As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

Twenty years ago, drug discovery ran on a simple script of screening compounds and hoping for a hit. This exclusive ebook, ...

The ISTAND program is designed to advance promising, high-impact New Approach Methodologies (NAMs) through structured FDA engagement to inform regulatory decision-making. Acceptance of Axion’s LOI ...

Salt Lake City, Utah, February 9, 2026 – Carterra Inc., the leading provider of technologies enabling high-throughput biology, today announced the launch of the Carterra Vega High-Throughput Surface ...

Traditional animal models remain an important part of preclinical research, but species differences can limit translation of ...

Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that ...

The biotechnology industry is moving past the initial excitement of artificial intelligence (AI) to confront a more complex reality: the transition from isolated digital tools to fully integrated, ...

Over the past decade, few areas of medicine have captured both scientific and public attention as dramatically as GLP-1 (glucagon-like peptide-1)-based therapies. First developed for diabetes, GLP-1 ...

Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease (MND) in which the motor neurons are gradually lost. As these neurons deteriorate, patients experience muscle weakness, twitching, ...

A scientist who assumes there is one authoritative FDA AI drug development guidance document to read would be forgiven, and wrong. The reality is closer to a paper trail: a 2021 action plan that most ...

From AI agents to cell therapy to Alzheimer’s drug pipelines, this issue follows the same problem across three fields:what it takes to turn something that works once into something that works at scale ...